drugset / Trial / NCT06560632
Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, open-label Phase 1 trial to investigate the safety, PK, and pharmacodynamics of the Polθ inhibitor RP-3467 alone or in combination with the poly-ADP ribose polymerase inhibitor (PARPi) olaparib in adults with molecularly selected advanced solid tumors.
Timeline
- Start
- 2024-09-17
- Primary completion
- 2025-10-28
- Completion
- 2025-10-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaparib | Small molecule | 200 mg | — |
| Subject | Olaparib | Small molecule | 300 mg | — |
| Subject | RP-3467 | Unknown | — | Oral |